Mark Barker, Author at Journal for Clinical Studies - Page 134 of 338

Current Edition

Volume 17 Issue 3

Europe

The $95 billion biotech Gilead just announced plans to test a promising potential coronavirus treatment in 1,000 people

The $95 billion biotech Gilead Sciences is accelerating its effort to test a promising drug to treat COVID-19, the disease caused by the spreading coronavirus outbre...

27 February 2020 Europe | Regional News

Continue Reading →

Europe

First UK clinical trial to identify, assess and treat hepatitis C patients found to be effective

A University of Bristol-led clinical trial to increase the identification and treatment of hepatitis C (HCV) patients in primary care has found to be effective, acce...

27 February 2020 Europe | Regional News

Continue Reading →

Europe

Clinerion partners with Wefight to optimize patient recruitment in clinical trials by leveraging artificial intelligence to identify eligible patients from Vik community

Clinerion’s Patient Network Explorer platform allows clinical trial sponsors to identify cohorts of patients eligible for recruitment from its global network of part...

27 February 2020 Europe | Regional News

Continue Reading →

Boosting Trial Success through Blinded Data Analytics: What Can We Learn from CNS?

Volume 12 Issue 1

Boosting Trial Success through Blinded Data Analytics: What Can We Learn from CNS?

Research scientists know that data alone does not lie – but data can mislead. That’s especially true in clinical trials that rely on subjective endpoints to assess d...

20 February 2020 Volume 12 Issue 1

Continue Reading →

FDA Guidance on Less Common Viral Hepatitis Type

Volume 12 Issue 1

FDA Guidance on Less Common Viral Hepatitis Type

The US Food and Drug Administration (FDA) recently revisited the topic of drugs for liver infection through a newly issued guidance document on hepatitis D virus (HD...

20 February 2020 Volume 12 Issue 1

Continue Reading →

IDMP at a Crossroads

Volume 12 Issue 1

IDMP at a Crossroads

Providing annual reviews on IDMP progress has proved painful in recent years because momentum has not always been where it should be, due to shifting timescales and ...

20 February 2020 Volume 12 Issue 1

Continue Reading →

Merger and Acquisition in Healthcare

Volume 12 Issue 1

Merger and Acquisition in Healthcare

Healthcare mergers and acquisitions have been the cause of extensive debate across the medical industry, calling into question the tools and scale necessary to thriv...

20 February 2020 Volume 12 Issue 1

Continue Reading →

The Use of Modelling and Simulation Studies in Early-phase Clinical Trials

Volume 12 Issue 1

The Use of Modelling and Simulation Studies in Early-phase Clinical Trials

Improving experimental drug success rate and accelerating clinical development are top priorities for pharmaceutical and biotech companies. Careful and considered de...

20 February 2020 Volume 12 Issue 1

Continue Reading →

The Biggest Regulatory Moments of 2019 & How They’ll Impact 2020

Volume 12 Issue 1

The Biggest Regulatory Moments of 2019 & How They’ll Impact 2020

2019 saw many noteworthy changes in the regulatory industry. In April 2019 it was announced that the FDA’s Office of New Drugs (OND) would create enhanced review zon...

20 February 2020 Volume 12 Issue 1

Continue Reading →

Rescue Trials – When Should You Call for Help?

Volume 12 Issue 1

Rescue Trials – When Should You Call for Help?

Although previously very rare, more and more trials are becoming in need of 'rescue' as competition for resources means less experienced staff are left to manage unf...

20 February 2020 Volume 12 Issue 1

Continue Reading →